@FiercePharma: Got an idea for an FDA drug study? Send an email. Editor's corner | Follow @FiercePharma
@EricPFierce: Our Twitter chat is less than an hour off. Don't miss the discussion on #sustainedrelease with BASF expert Thorsten Cech. @BASF_Pharma | Follow @EricPFierce
@CarlyHFierce: Roche's MS hopeful will amp up payer pricing pressure, analyst says. Article | Follow @CarlyHFierce
> GlaxoSmithKline ($GSK) has asked a federal judicial panel to consolidate a dozen lawsuits alleging that its antinausea medication Zofran can cause birth defects. More
> Bloodthinners, antidepressants, diabetes drugs and Viagra helped the number of prescriptions dispensed in England rise 3.3% last year. Report
> Eisai's epilepsy treatment Fycompa has launched in the U.K. Report
> In Israel, life sciences upstarts are struggling to follow the lead of local generics giant Teva ($TEVA). Story
> U.K. Chancellor George Osborne has committed to increasing NHS funding by £8 billion a year. More
> Pet pharmaceuticals group Dechra says its revenue for the year is up by about 10%. More
Medical Device News
@FierceMedDev: ICYMI yesterday: Mindray down on the acquisition of remainder of Chinese orthopedics company for $72.6M. Article | Follow @FierceMedDev
@EmilyWFierce: JAMA: Mammography does not reduce breast cancer deaths, could result in overdiagnosis. Story | Follow @EmilyWFierce
> Theranos signs its first health insurer in a deal with Capital BlueCross. More
> Device makers to offer stronger guarantees on products if they fail to perform. Story
Biotech News
@FierceBiotech: Who should make this year's Fierce 15? Nominate the most promising private biotechs. Nomination form | Follow @FierceBiotech
@JohnCFierce: Novartis says Entresto will be priced at $12.50 a day. More | Follow @JohnCFierce
@DamianFierce: Entresto, described by $NVS CEO Joe Jimenez as a "multi-blockbuster," is now approved to treat heart failure. More | Follow @DamianFierce
> Sanofi advances a one-shot malaria program as drug resistance spreads. Article
> AstraZeneca, Ironwood score PhIII success in China. Item
Biotech Research News
> UC San Diego accuses USC of conspiring to grab Alzheimer's research, funding. Report
> Computer scientists warn about the coming tsunami of genomics data. News
> Falsely accused 'Rambo' protein actually guards against heart failure. More
> UCSD researchers point to promising new drug target for glioblastoma. Story
> Researchers launch PhI study to test new approach to T cell immunotherapy. Article
Diagnostics News
> Theranos nabs FDA clearance for finger-stick herpes test. More
> BG Medicine gets FDA blessing for automated chronic heart failure test. Report
> Natera bags $180M in IPO to ramp up R&D. News
> Epic Sciences and LabCorp expand global reach with Asia clinical trials deal. Story
> Quest and Quintiles rev up new lab testing JV. Article
Pharma Marketing News
> Roche's MS hopeful will amp up payer pricing pressure, analyst says. News
> Bydureon, Invokana, Xarelto brand teams shelled out most to doctors in 2014. Article
> Merck, Samsung rack up data on Humira biosim, setting stage for approval apps. More
> Pfizer's Viagra first ED drug available in single-dose packets. Story
> Early Avycaz sales could signal bigger payoff for superbug-fighting antibiotics. Report
And Finally... CVS Health ($CVS) is withdrawing its membership from the U.S. Chamber of Commerce after media reports that the trade group was lobbying globally against antismoking laws. News